Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Lee430on Sep 12, 2023 8:12am
126 Views
Post# 35630924

RE:RE:Any thoughts?

RE:RE:Any thoughts?Considering the guidance Thera gave us for the trial restart date and the statement "quickly enroll patients" I feel an update/explanation is overdue...Maybe addresing this is one of the reasons for their early Q3 date.
SPCEO1 wrote: My cousin had to be off her old chemo for a month before she could start on he earlier trial. With testing and other stuff needed to get done, it may have been almost 6 weeks between when she decided to move forward and when she was first dosed. 

Also, being off chemo for that long isn't helpful at this stage of the diease. That is a disincentive for still somewhat healthy patients to join a new trial. 

And there are competing options out there. Having paused the previous trial, an average somewhat healthier patient may opt for a new drug option without any black marks on it. The cost of getting healthier patients may be greater difficulty in convincing them to join your trial. 

Wino115 wrote: Why has it taken longer than it should to find Patient #1 for the P1 trial?
Which of these reasons is right or wrong?

Criteria making it hard?   (To me, not that different than most trials.)
No incentive from Drs as clinic payments may be lowered?
Biopsy lengthen's time - I don't think they're doing the Sort1 staining, but could be wrong?
Patients picking other similar target-drug trials so being crowded out given past results and small size?






<< Previous
Bullboard Posts
Next >>